Biosimilars, Clinical Development and Clinical Supply

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biosimilars

Clinical Development

Clinical Supply

Rapid delivery of toxicological material

Drug Target Review

SEPTEMBER 10, 2024

Drug developer companies across the pharma industry report notable reductions in drug development timelines where 10 to 12 months, from lead monoclonal antibody (mAb) identification to IND application, is the new norm and in which earlier Tox material generation has been a critical component for shortening IND timelines.

Drug Development

Drug Development Clinical Supply Production FDA

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

OCTOBER 27, 2020

Upon option exercise, Novartis would be responsible for all further development and commercialization activities. During the clinical development stage, Molecular Partners will provide clinical supply.

Therapies

Therapies Virus Treatment Clinical Trials

Drug Discovery Digest

Rapid delivery of toxicological material

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

Stay Connected